Radiation therapy equipment developer RefleXion Medical has received a $60 million loan from Oxford Finance to develop its biology-guided radiotherapy (BgRT) system for targeted cancer treatment.
The company plans to use the funds to complete the process of market clearance from the U.S. Food and Drug Administration (FDA) and the product's subsequent commercial launch.
RefleXion's BgRT is designed to use CT and PET imaging to guide personalized radiotherapy. The patented technology prompts tumors to continuously signal their location during cancer treatment.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
